SLAMF7 and Miyoshi myopathy: Elotuzumab is an FDA approved monoclonal antibody for treatment of MM, which exhibits a dual mechanism of action through direct NK cell activation when bound to SLAMF7 on its surface or by antibody dependent cellular cytotoxicity (ADCC)25,26.